GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward…
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
July 02, 2025 01:00 ET Â | Source: BioVersys Ad hoc announcement pursuant…
Radware Schedules Conference Call for Its Second Quarter 2025 Earnings
TEL AVIV, Israel, July 02, 2025 (GLOBE NEWSWIRE) -- Radware® (NASDAQ: RDWR),…
Quantexa Named a Luminary in Everest Groups Innovation Watch Report
LONDON, July 02, 2025 (GLOBE NEWSWIRE) -- Quantexa, a global leader in…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET Â | Source: Instil Bio US phase 1…
The Ensign Group Purchases Skilled Nursing Facility in Texas
July 02, 2025 06:00 ET Â | Source: The Ensign Group, Inc. SAN…
The Ensign Group Continues Growth in Idaho
July 02, 2025 06:00 ET Â | Source: The Ensign Group, Inc. SAN…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
July 02, 2025 03:00 ET Â | Source: Belite Bio, Inc -Â 500…
OSE Immunotherapeutics met jour linformation sur les procdures en cours
OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2,…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…